Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors - Related Studies

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

This study is currently recruiting participants.

Study NCT00602082. Last updated on October 8, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Gastrointestinal Carcinoid Tumor
		Islet Cell Tumor

2	Additional conditions recognized in this trial
		Adenoma, Islet Cell
		Carcinoid Tumor
		Gastrointestinal Neoplasms
		Malignant Carcinoid Syndrome
		Neuroendocrine Tumors

3	More general conditions related to this trial
		Adenocarcinoma
		Adenoma
		Carcinoma
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Gastrointestinal Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Pancreatic Diseases
		Pancreatic Neoplasms

4	Interventions listed in this trial
		capecitabine
		cisplatin
		streptozocin
		DNA analysis
		RNA analysis
		laboratory biomarker analysis
		protein analysis
		proteomic profiling

5	More general drug interventions related to this trial
		Antibiotics, Antineoplastic
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Cambridge University Hospitals NHS Foundation Trust